Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial

BACKGROUND: Rheumatoid arthritis (RA), a chronic systemic autoimmune disease, is characterized by synovitis and progressive damage to the bone and cartilage of the joints, leading to disability and reduced quality of life. This study was a randomized clinical trial comparing the outcomes between wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mengyan, Xue, Yu, Du, Fang, Ma, Lili, Lu, Liang-jing, Jiang, Lindi, Tao, Yi-Li, Yang, Chengde, Shi, Hui, Liu, Honglei, Cheng, Xiaobing, Ye, Junna, Su, Yutong, Zhao, Dongbao, Dai, Sheng-Ming, Teng, Jialin, Hu, Qiongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106157/
https://www.ncbi.nlm.nih.gov/pubmed/36848153
http://dx.doi.org/10.1097/CM9.0000000000002561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106157/
https://www.ncbi.nlm.nih.gov/pubmed/36848153
http://dx.doi.org/10.1097/CM9.0000000000002561

Ejemplares similares